TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Resistance
Scientists at Rockefeller University target drug resistance
October 28th, 2008
According to recent research published in the journal Antimicrobial Agents and Chemotherapy, "Multidrug-resistant strains of Staphylococcus aureus continue to increase in frequency worldwide, both in hospitals and in the community, raising serious problems for the chemotherapy of staphylococcal disease. Ceftobiprole (BPR; BAL9141), the active constituent of the prodrug ceftobiprole medocaril (BAL5788), is a new cephalosporin which was already shown to have powerful activity against a number of bacterial pathogens, including S. aureus." "In an effort to test possible limits to the antibacterial spectrum and efficacy of BPR, we examined the susceptibilities of the...
Source: TB & Outbreaks Week (2008-10-28)
|
